|
Azoospermia
|
0.300 |
Biomarker
|
disease |
CTD_human |
X chromosome-wide identification of SNVs in microRNA genes and non-obstructive azoospermia risk in Han Chinese population.
|
27107421 |
2016 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, our study demonstrates that miR-506 may act as a tumor suppressor in GC and that the miR-506/Yap1 axis may help us better understand the molecular mechanisms of GC progression.
|
25846731 |
2015 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer.
|
26362716 |
2015 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, our results suggest that miR-506 may function as a tumor suppressor and targets and inhibits ZEB2 in gastric carcinoma.
|
30923258 |
2019 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
This study investigated the role of miR-506 in survival and the EMT in patients with gastric cancer.
|
25707493 |
2015 |
|
Stomach Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Therefore, it was hypothesized in our study that NEAT1 can be recognized as a competing endogenous RNA to modulate STAT3 by sponging miR-506 in GC.
|
29363783 |
2019 |
|
Malignant neoplasm of ovary
|
0.050 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.
|
30105876 |
2018 |
|
Malignant neoplasm of ovary
|
0.050 |
Biomarker
|
disease |
BEFREE |
This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.
|
24604117 |
2014 |
|
Malignant neoplasm of ovary
|
0.050 |
Biomarker
|
disease |
BEFREE |
Finally, the regulatory effect of LINC01308/miRNA-506 on OC cell behaviors was examined through a series of rescue experiments.
|
31081077 |
2019 |
|
Malignant neoplasm of ovary
|
0.050 |
Biomarker
|
disease |
BEFREE |
Nanoparticle delivery of miR-506 in orthotopic OvCa mouse models led to E-cadherin induction and reduced tumor growth.
|
23410973 |
2013 |
|
Malignant neoplasm of ovary
|
0.050 |
Biomarker
|
disease |
BEFREE |
MiR-506 is a robust clinical marker for chemotherapy response and survival in serous ovarian cancers and has important therapeutic value in sensitizing cancer cells to chemotherapy.
|
25995442 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
This newly recognized miR-506-CDK4/6-FOXM1 axis provides further insight into the pathogenesis of ovarian carcinoma and identifies a potential novel therapeutic agent.
|
24604117 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
Finally, the regulatory effect of LINC01308/miRNA-506 on OC cell behaviors was examined through a series of rescue experiments.
|
31081077 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
Introduction of miR-506, mediated by nanoparticle delivery, in EOC orthotopic mouse models resulted in decreased vimentin, N-cad, and SNAI2 expression and increased E-cad expression; it also suppressed the dissemination of EOC cells.
|
25230372 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
Nanoparticle delivery of miR-506 in orthotopic OvCa mouse models led to E-cadherin induction and reduced tumor growth.
|
23410973 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.
|
30105876 |
2018 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We found a significant elevated expression of both examined microRNAs in early CRC patients when compared to those in healthy individuals (p = 0.0054 for miR-506 and p = 0.0025 for miR-4316).
|
28405738 |
2017 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data showed that miR-124 and miR-506 inhibit progression and increase sensitivity to chemotherapy by targeting DNMT3B and DNMT1 in CRC.
|
26497367 |
2015 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In the present study, in ISH and qRT-PCR results demonstrated that miR-506 is weakly expressed in chemoresistant CRC tissues.
|
28217977 |
2017 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Spearman correlation analysis revealed that expression of NR4A1 mRNA was negatively correlated with miR-506 levels in colorectal cancer tissue.
|
31293661 |
2019 |
|
Malignant neoplasm of stomach
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-506 was identified as an ETS1 targeting suppressor of metastatic invasion and angiogenesis in gastric cancer.
|
26362716 |
2015 |
|
Malignant neoplasm of stomach
|
0.040 |
Biomarker
|
disease |
BEFREE |
Therefore, it was hypothesized in our study that NEAT1 can be recognized as a competing endogenous RNA to modulate STAT3 by sponging miR-506 in GC.
|
29363783 |
2019 |
|
Malignant neoplasm of stomach
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study investigated the role of miR-506 in survival and the EMT in patients with gastric cancer.
|
25707493 |
2015 |
|
Malignant neoplasm of stomach
|
0.040 |
Biomarker
|
disease |
BEFREE |
Thus, our study demonstrates that miR-506 may act as a tumor suppressor in GC and that the miR-506/Yap1 axis may help us better understand the molecular mechanisms of GC progression.
|
25846731 |
2015 |
|
Pancreatic carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Rosmarinic inhibits cell proliferation, invasion and migration via up-regulating miR-506 and suppressing MMP2/16 expression in pancreatic cancer.
|
31060006 |
2019 |